US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Nasus Pharma Ltd.

7.33

+0.718110.86%

Post-market: 7.330.00000.00%16:04 EST

Volume:1.78K

Turnover:12.35K

Market Cap:66.42M

PE:-33.62

High:7.33

Open:6.75

Low:6.63

Close:6.61

52wk High:9.99

52wk Low:5.90

Shares:9.06M

Float Shares:3.98M

Volume Ratio:2.76

T/O Rate:0.04%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.2180

EPS(LYR):-0.2180

ROE:--

ROA:-116.06%

PB:-20.68

PE(LYR):-33.62

Loading ...

Overview Company News Filings

Nasus Pharma Appoints Eyal Rubin as New CFO to Enhance Leadership

BRIEF-Nasus Pharma Strengthens Leadership Team, Appointing Eyal Rubin As Executive Vice President And Chief Financial Officer

Nasus Pharma Initiates Phase 2 Study of Needle-Free Epinephrine

BRIEF-Nasus Pharma Announces Initiation Of Phase 2 Clinical Study Of Ns002 With First Participant Dosed

Nasus Pharma Ltd - Interim Results Expected in Q1 2026

THOMSON REUTERS

Nasus Pharma Announces Approval from Health Canada to Initiate Planned Phase 2 Clinical Study of NS002 Intranasal Epinephrine Powder

Nasus Pharma Expands Collaboration with Aptar for Intranasal Epinephrine Program

BRIEF-Nasus Pharma Announces Expanded Agreement To Support Development And Commercialization Of Ns002 Intranasal Epinephrine Program

Nasus Pharma announces expanded agreement to support NS002

Nasus Pharma Announces Expanded Agreement to Support Development and Commercialization of Ns002 Intranasal Epinephrine Program

THOMSON REUTERS

Nasus Pharma Ltd. Secures Additional Funding from IPO Over-Allotment

Amex Halt Add Info Lst 5.920000

THOMSON REUTERS

Nasus Pharma Initiated at Buy by Laidlaw & Co.

Nasus Pharma initiated with a Buy at Laidlaw

Nasus Pharma Announces Upcoming Presentation at H.C. Wainwright 27th Annual Global Investment Conference

Nasus Pharma Marks Nyse American Listing With Bell Ringing Ceremony

THOMSON REUTERS

Nasus Pharma Marks NYSE American Listing with Bell Ringing Ceremony

Nasus Pharma Announces Closing of Initial Public Offering

Stock Track | Nasus Pharma (NSRX) Soars 13.67% in Trading Debut Following $10 Million IPO

Stock Track | Nasus Pharma Soars 13.67% in NYSE Debut Following $10 Million IPO

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/NSRX/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NSRX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NSRX\",,,,,undefined,":{"symbol":"NSRX","market":"US","secType":"STK","nameCN":"Nasus Pharma Ltd.","latestPrice":7.3287,"timestamp":1764709200000,"preClose":6.6106,"halted":0,"volume":1775,"hourTrading":{"tag":"盘后","latestPrice":7.3287,"preClose":7.3287,"latestTime":"16:04 EST","volume":1,"amount":7.3287,"timestamp":1764709451353},"delay":0,"floatShares":3982680,"shares":9063458,"eps":-0.217993,"marketStatus":"Post-Mkt","change":0.7181,"latestTime":"12-02 17:09:20 EST","open":6.75,"high":7.3287,"low":6.63,"amount":12354.0984,"amplitude":0.105694,"askPrice":9.05,"askSize":100,"bidPrice":2.67,"bidSize":200,"shortable":3,"etf":0,"ttmEps":-0.217993,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1764723600000},"marketStatusCode":4,"adr":0,"listingDate":1755057600000,"exchange":"NASDAQ","adjPreClose":6.6106,"postHourTrading":{"tag":"盘后","latestPrice":7.3287,"preClose":7.3287,"latestTime":"16:04 EST","volume":1,"amount":7.3287,"timestamp":1764709451353},"volumeRatio":2.757068},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NSRX\",,,,,undefined,":{"symbol":"NSRX","floatShares":3982680,"roa":"-116.06%","roe":"--","lyrEps":-0.217993,"volumeRatio":2.757068,"shares":9063458,"dividePrice":0,"high":7.3287,"amplitude":0.105694,"preClose":6.6106,"low":6.63,"week52Low":5.9,"pbRate":"-20.68","week52High":9.9899,"institutionHeld":0,"latestPrice":7.3287,"committee":0.333333,"eps":-0.217993,"divideRate":0,"volume":1775,"delay":0,"ttmEps":-0.217993,"open":6.75,"prevYearClose":8,"prevWeekClose":7,"prevMonthClose":7,"prevQuarterClose":6.65,"fiveDayClose":7.25,"twentyDayClose":7.61,"sixtyDayClose":8.01},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NSRX\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NSRX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NSRX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":1,"updateTime":1759294800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/NSRX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"NSRX","date":"2025-12-01","current":-33.618969,"percent":0.88,"low":-51.389177,"twenty":-47.66361,"median":-46.687866,"eighty":-42.991866,"high":-35.481595,"avg":-45.597413,"sd":2.995208,"marketCap":63417438},"quantilePoints":[{"date":"2025-08-15","current":-47.343663,"twenty":-48.284655,"median":-47.931783,"eighty":-47.578911,"marketCap":72530491},{"date":"2025-08-22","current":-50.265593,"twenty":-50.691372,"median":-49.082873,"eighty":-48.024103,"marketCap":77006889},{"date":"2025-08-29","current":-47.604473,"twenty":-50.029049,"median":-48.047994,"eighty":-47.509856,"marketCap":72930053},{"date":"2025-09-05","current":-47.370886,"twenty":-49.082873,"median":-47.841017,"eighty":-47.486202,"marketCap":72572198},{"date":"2025-09-12","current":-48.136697,"twenty":-48.519903,"median":-47.66361,"eighty":-47.343663,"marketCap":73745420},{"date":"2025-09-19","current":-47.384488,"twenty":-48.195834,"median":-47.722745,"eighty":-47.36793,"marketCap":72593035},{"date":"2025-09-26","current":-47.604473,"twenty":-48.136697,"median":-47.604473,"eighty":-47.343663,"marketCap":72930053},{"date":"2025-10-03","current":-36.900859,"twenty":-48.077561,"median":-47.51577,"eighty":-47.308794,"marketCap":56532116},{"date":"2025-10-10","current":-45.830394,"twenty":-48.047993,"median":-47.384488,"eighty":-45.830394,"marketCap":70212163},{"date":"2025-10-17","current":-46.835706,"twenty":-47.900153,"median":-47.36793,"eighty":-45.534713,"marketCap":71752301},{"date":"2025-10-24","current":-44.943354,"twenty":-47.900153,"median":-47.314116,"eighty":-44.943354,"marketCap":68853218},{"date":"2025-10-31","current":-46.007802,"twenty":-47.900153,"median":-47.308794,"eighty":-45.239034,"marketCap":70483952},{"date":"2025-11-07","current":-44.647674,"twenty":-47.781881,"median":-47.308794,"eighty":-44.943354,"marketCap":68400236},{"date":"2025-11-14","current":-46.717433,"twenty":-47.722745,"median":-47.22009,"eighty":-44.647674,"marketCap":71571108},{"date":"2025-11-21","current":-41.395195,"twenty":-47.722745,"median":-46.835706,"eighty":-44.351994,"marketCap":63417438},{"date":"2025-11-28","current":-41.395195,"twenty":-47.675437,"median":-46.717433,"eighty":-43.654189,"marketCap":63417438},{"date":"2025-12-01","current":-41.395195,"twenty":-47.66361,"median":-46.687866,"eighty":-42.991866,"marketCap":63417438}],"updateTime":1764711642234},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NSRX\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2584373541","title":"Nasus Pharma Appoints Eyal Rubin as New CFO to Enhance Leadership","url":"https://stock-news.laohu8.com/highlight/detail?id=2584373541","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584373541?lang=en_us&edition=fundamental","pubTime":"2025-11-20 21:55","pubTimestamp":1763646914,"startTime":"0","endTime":"0","summary":"An announcement from Nasus Pharma Ltd. ( ($NSRX) ) is now available. Nasus Pharma Ltd. announced the appointment of Eyal Rubin as Executive Vice Pr...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/nasus-pharma-appoints-eyal-rubin-as-new-cfo-to-enhance-leadership?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/nasus-pharma-appoints-eyal-rubin-as-new-cfo-to-enhance-leadership?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","NSRX"],"gpt_icon":0},{"id":"2584986134","title":"BRIEF-Nasus Pharma Strengthens Leadership Team, Appointing Eyal Rubin As Executive Vice President And Chief Financial Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2584986134","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584986134?lang=en_us&edition=fundamental","pubTime":"2025-11-20 21:15","pubTimestamp":1763644522,"startTime":"0","endTime":"0","summary":"BRIEF-Nasus Pharma Strengthens Leadership Team, Appointing Eyal Rubin As Executive Vice President And Chief Financial OfficerNasus Pharma Ltd NSRX.A:NASUS PHARMA STRENGTHENS LEADERSHIP TEAM, APPOINTIN","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251120:nTUA8HFN8B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NSRX","BK4007"],"gpt_icon":0},{"id":"2584958035","title":"Nasus Pharma Initiates Phase 2 Study of Needle-Free Epinephrine","url":"https://stock-news.laohu8.com/highlight/detail?id=2584958035","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584958035?lang=en_us&edition=fundamental","pubTime":"2025-11-18 21:47","pubTimestamp":1763473675,"startTime":"0","endTime":"0","summary":"The latest update is out from Nasus Pharma Ltd. ( ($NSRX) ). On November 18, 2025, Nasus Pharma Ltd. announced the initiation of a Phase 2 clinical...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/nasus-pharma-initiates-phase-2-study-of-needle-free-epinephrine?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/nasus-pharma-initiates-phase-2-study-of-needle-free-epinephrine?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NSRX","BK4007"],"gpt_icon":0},{"id":"2584937088","title":"BRIEF-Nasus Pharma Announces Initiation Of Phase 2 Clinical Study Of Ns002 With First Participant Dosed","url":"https://stock-news.laohu8.com/highlight/detail?id=2584937088","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584937088?lang=en_us&edition=fundamental","pubTime":"2025-11-18 21:09","pubTimestamp":1763471364,"startTime":"0","endTime":"0","summary":"BRIEF-Nasus Pharma Announces Initiation Of Phase 2 Clinical Study Of Ns002 With First Participant DosedNasus Pharma Ltd NSRX.A:NASUS PHARMA ANNOUNCES INITIATION OF PHASE 2 CLINICAL STUDY OF NS002 WITH","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251118:nTUACHCJVL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NSRX"],"gpt_icon":0},{"id":"2584937724","title":"Nasus Pharma Ltd - Interim Results Expected in Q1 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2584937724","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584937724?lang=en_us&edition=fundamental","pubTime":"2025-11-18 21:00","pubTimestamp":1763470803,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251118:nTUACHCJVL:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","NSRX"],"gpt_icon":0},{"id":"2581095408","title":"Nasus Pharma Announces Approval from Health Canada to Initiate Planned Phase 2 Clinical Study of NS002 Intranasal Epinephrine Powder","url":"https://stock-news.laohu8.com/highlight/detail?id=2581095408","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581095408?lang=en_us&edition=fundamental","pubTime":"2025-11-06 21:00","pubTimestamp":1762434000,"startTime":"0","endTime":"0","summary":"Positive Regulatory Response Marks Important Milestone for NS002 Development ProgramTEL AVIV, Nov.  06, 2025  (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) (“Nasus Pharma” or the “Company”), a cl","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/06/3182540/0/en/Nasus-Pharma-Announces-Approval-from-Health-Canada-to-Initiate-Planned-Phase-2-Clinical-Study-of-NS002-Intranasal-Epinephrine-Powder.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NSRX","BK4006","BK4520","BK4516","BK4588","X","BK4585","BK4007"],"gpt_icon":0},{"id":"2573286929","title":"Nasus Pharma Expands Collaboration with Aptar for Intranasal Epinephrine Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2573286929","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573286929?lang=en_us&edition=fundamental","pubTime":"2025-10-08 21:27","pubTimestamp":1759930067,"startTime":"0","endTime":"0","summary":"The latest announcement is out from Nasus Pharma Ltd. ( ($NSRX) ). On October 6, 2025, Nasus Pharma Ltd. extended its collaboration with AptarGroup...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/nasus-pharma-expands-collaboration-with-aptar-for-intranasal-epinephrine-program?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/nasus-pharma-expands-collaboration-with-aptar-for-intranasal-epinephrine-program?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","NSRX"],"gpt_icon":0},{"id":"2573923136","title":"BRIEF-Nasus Pharma Announces Expanded Agreement To Support Development And Commercialization Of Ns002 Intranasal Epinephrine Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2573923136","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573923136?lang=en_us&edition=fundamental","pubTime":"2025-10-08 20:25","pubTimestamp":1759926337,"startTime":"0","endTime":"0","summary":"BRIEF-Nasus Pharma Announces Expanded Agreement To Support Development And Commercialization Of Ns002 Intranasal Epinephrine ProgramOct 8 (Reuters) - Nasus Pharma Ltd NSRX.A:NASUS PHARMA ANNOUNCES EXP","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251008:nTUA1RR9JC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NSRX","BK4007"],"gpt_icon":0},{"id":"2573923948","title":"Nasus Pharma announces expanded agreement to support NS002","url":"https://stock-news.laohu8.com/highlight/detail?id=2573923948","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573923948?lang=en_us&edition=fundamental","pubTime":"2025-10-08 20:17","pubTimestamp":1759925823,"startTime":"0","endTime":"0","summary":"Nasus Pharma (NSRX) announced the execution of comprehensive agreements with Aptar France S.A.S. and AptarGroup (ATR) to support the ongoing clinic...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/nasus-pharma-announces-expanded-agreement-to-support-ns002-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/nasus-pharma-announces-expanded-agreement-to-support-ns002-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NSRX","ATR","BK4007","BK4126"],"gpt_icon":0},{"id":"2573282659","title":"Nasus Pharma Announces Expanded Agreement to Support Development and Commercialization of Ns002 Intranasal Epinephrine Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2573282659","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573282659?lang=en_us&edition=fundamental","pubTime":"2025-10-08 20:04","pubTimestamp":1759925040,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251008:nTUA1RR9JC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NSRX","BK4007"],"gpt_icon":0},{"id":"2572749023","title":"Nasus Pharma Ltd. Secures Additional Funding from IPO Over-Allotment","url":"https://stock-news.laohu8.com/highlight/detail?id=2572749023","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572749023?lang=en_us&edition=fundamental","pubTime":"2025-10-01 04:38","pubTimestamp":1759264733,"startTime":"0","endTime":"0","summary":"Nasus Pharma Ltd. ( ($NSRX) ) just unveiled an announcement. On September 30, 2025, Nasus Pharma Ltd. announced the closure of a partial exercise o...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/nasus-pharma-ltd-secures-additional-funding-from-ipo-over-allotment?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/nasus-pharma-ltd-secures-additional-funding-from-ipo-over-allotment?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","NSRX"],"gpt_icon":0},{"id":"2571325848","title":"Amex Halt  Add Info Lst 5.920000","url":"https://stock-news.laohu8.com/highlight/detail?id=2571325848","media":"THOMSON REUTERS","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571325848?lang=en_us&edition=fundamental","pubTime":"2025-09-30 21:43","pubTimestamp":1759239782,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250930:nAQN2L1GGK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NSRX","BK4007"],"gpt_icon":0},{"id":"2571335504","title":"Nasus Pharma Initiated at Buy by Laidlaw & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2571335504","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571335504?lang=en_us&edition=fundamental","pubTime":"2025-09-29 20:32","pubTimestamp":1759149120,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NSRX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  September 29, 2025 08:32 ET (12:32 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NSRX","BK4007"],"gpt_icon":0},{"id":"2571638373","title":"Nasus Pharma initiated with a Buy at Laidlaw","url":"https://stock-news.laohu8.com/highlight/detail?id=2571638373","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571638373?lang=en_us&edition=fundamental","pubTime":"2025-09-29 16:45","pubTimestamp":1759135509,"startTime":"0","endTime":"0","summary":"Laidlaw analyst Yale Jen initiated coverage of Nasus Pharma (NSRX) with a Buy rating and $22 price target The firm says Nasus is a mid-clinical sta...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/nasus-pharma-initiated-with-a-buy-at-laidlaw-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/nasus-pharma-initiated-with-a-buy-at-laidlaw-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","NSRX"],"gpt_icon":0},{"id":"2564804062","title":"Nasus Pharma Announces Upcoming Presentation at H.C. Wainwright 27th Annual Global Investment Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2564804062","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564804062?lang=en_us&edition=fundamental","pubTime":"2025-09-02 20:00","pubTimestamp":1756814400,"startTime":"0","endTime":"0","summary":"TEL AVIV, Israel, Sept.  02, 2025  (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) (“Nasus Pharma” or the “Company”), a clinical-stage pharmaceutical company focused on the development of innovativ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/09/02/3142595/0/en/Nasus-Pharma-Announces-Upcoming-Presentation-at-H-C-Wainwright-27th-Annual-Global-Investment-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NSRX"],"gpt_icon":0},{"id":"2562473377","title":"Nasus Pharma Marks Nyse American Listing With Bell Ringing Ceremony","url":"https://stock-news.laohu8.com/highlight/detail?id=2562473377","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562473377?lang=en_us&edition=fundamental","pubTime":"2025-08-26 20:00","pubTimestamp":1756209600,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250826:nTUABCYFPF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NSRX"],"gpt_icon":0},{"id":"2562736624","title":"Nasus Pharma Marks NYSE American Listing with Bell Ringing Ceremony","url":"https://stock-news.laohu8.com/highlight/detail?id=2562736624","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562736624?lang=en_us&edition=fundamental","pubTime":"2025-08-26 20:00","pubTimestamp":1756209600,"startTime":"0","endTime":"0","summary":"TEL AVIV, Israel, Aug.  26, 2025  (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) (“Nasus Pharma” or the “Company”), a clinical-stage pharmaceutical company focused on the development of innovative","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/08/26/3139216/0/en/Nasus-Pharma-Marks-NYSE-American-Listing-with-Bell-Ringing-Ceremony.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4117","NSRX","AFG","NYSE","BK4107"],"gpt_icon":0},{"id":"2559412964","title":"Nasus Pharma Announces Closing of Initial Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2559412964","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559412964?lang=en_us&edition=fundamental","pubTime":"2025-08-15 04:05","pubTimestamp":1755201900,"startTime":"0","endTime":"0","summary":"TEL AVIV, Israel, Aug.  14, 2025  (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) (“Nasus Pharma” or the “Company”), a clinical-stage pharmaceutical company focused on the development of innovative","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/08/14/3133840/0/en/Nasus-Pharma-Announces-Closing-of-Initial-Public-Offering.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4233","NSRX","BK4528","BK4205","UK"],"gpt_icon":0},{"id":"1109809189","title":"Stock Track | Nasus Pharma (NSRX) Soars 13.67% in Trading Debut Following $10 Million IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=1109809189","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1109809189?lang=en_us&edition=fundamental","pubTime":"2025-08-13 22:16","pubTimestamp":1755094584,"startTime":"0","endTime":"0","summary":"Shares of Nasus Pharma Ltd. (NSRX) are soaring 13.67% in their trading debut on Wednesday, following the company's successful initial public offering (IPO). The clinical-stage pharmaceutical company,...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["NSRX"],"gpt_icon":0},{"id":"1148764485","title":"Stock Track | Nasus Pharma Soars 13.67% in NYSE Debut Following $10 Million IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=1148764485","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1148764485?lang=en_us&edition=fundamental","pubTime":"2025-08-13 22:16","pubTimestamp":1755094584,"startTime":"0","endTime":"0","summary":"Nasus Pharma Ltd. (NSRX) made a strong debut on the New York Stock Exchange, with its stock soaring 13.67% in intraday trading on Wednesday. The impressive rally comes after the clinical-stage...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["NSRX"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":23,"code":"91000000","status":"200"}]}}